Emerging Targets in Immuno-Oncology: From Checkpoint Inhibitors to CAR-T

The landscape of immuno-oncology has been revolutionized by checkpoint inhibitors and CAR-T cell therapies, yet the quest for novel drug targets continues to intensify. As of 2025, over 1,200 immuno-oncology agents are in clinical development, with approximately 60% targeting pathways beyond PD-1/PD-L1 and CTLA-4. This article explores emerging targets that promise to overcome resistance mechanisms, expand therapeutic indications, and improve patient outcomes. By analyzing recent clinical data, biomarker discoveries, and mechanistic insights, we provide a comprehensive overview of the next wave of immuno-oncology drug targets, from metabolic regulators to novel immune checkpoints.

1. Beyond PD-1: The Next Generation of Immune Checkpoints

While PD-1/PD-L1 inhibitors have transformed cancer care, resistance develops in 60-70% of patients. Emerging targets such as LAG-3, TIGIT, and VISTA are now entering late-stage trials. For example, relatlimab (anti-LAG-3) combined with nivolumab showed a 10.1-month median progression-free survival in melanoma, compared to 4.6 months with nivolumab alone (p<0.001). Similarly, tiragolumab (anti-TIGIT) plus atezolizumab achieved a 37% objective response rate in PD-L1-positive non-small cell lung cancer, versus 21% with atezolizumab alone. These data underscore the potential of dual checkpoint blockade to reinvigorate exhausted T cells.

2. Metabolic Checkpoints: Targeting the Tumor Microenvironment

Tumor metabolism creates an immunosuppressive niche. Key targets include adenosine A2A receptors, indoleamine 2,3-dioxygenase (IDO1), and glutaminase. In a Phase II trial, the A2A antagonist ciforadenant combined with atezolizumab yielded a 24% disease control rate in renal cell carcinoma. IDO1 inhibitors, despite earlier setbacks, are being re-evaluated with patient stratification. Recent data show that tumors with high tryptophan catabolism respond to IDO1 blockade, with a 15% overall response rate in biomarker-selected patients. Glutaminase inhibitors like telaglenastat are also under investigation, with preclinical models showing enhanced CD8+ T cell infiltration.

3. CAR-T Evolution: From CD19 to Solid Tumor Targets

CAR-T therapy has achieved 80-90% response rates in hematological malignancies, but solid tumors remain challenging. Emerging targets include B7-H3, mesothelin, and GD2. For B7-H3-targeted CAR-T, a Phase I trial in glioblastoma demonstrated a 50% reduction in tumor volume in 3 of 6 patients. Mesothelin-directed CAR-T combined with checkpoint inhibitors showed a 33% objective response rate in ovarian cancer. Additionally, 'armored' CAR-T cells secreting IL-12 or expressing dominant-negative TGF-β receptors are being tested, with early data showing improved persistence and tumor infiltration.

4. Innate Immune Targets: Engaging NK Cells and Macrophages

Beyond T cells, innate immune checkpoints offer new opportunities. Targets such as CD47 (macrophage checkpoint), NKG2A (NK cell checkpoint), and STING agonists are gaining traction. Magrolimab (anti-CD47) combined with azacitidine achieved a 67% complete response rate in myelodysplastic syndrome. Monalizumab (anti-NKG2A) plus cetuximab showed a 31% objective response rate in head and neck cancer. STING agonists, like ADU-S100, are being tested intratumorally, with 20% of patients achieving durable responses in Phase I trials. These targets leverage distinct immune compartments to overcome resistance.

5. Biomarker-Driven Target Selection: Precision Immuno-Oncology

Effective targeting requires robust biomarkers. Tumor mutational burden (TMB), microsatellite instability (MSI), and PD-L1 expression are established, but emerging biomarkers include interferon-gamma gene signatures, tumor-infiltrating lymphocyte density, and circulating tumor DNA. In a study of 1,500 patients, a composite biomarker combining TMB and T cell clonality predicted response to checkpoint inhibitors with 78% accuracy. Liquid biopsy-based dynamic monitoring is also enabling real-time target assessment, with ctDNA clearance correlating with a 90% 2-year survival rate in lung cancer patients.

6. Combination Strategies: Synergistic Target Pairings

Combining novel targets with established therapies is a key strategy. For example, a Phase III trial of the oncolytic virus talimogene laherparepvec (T-VEC) plus pembrolizumab showed a 48% objective response rate in melanoma, versus 25% with pembrolizumab alone. Similarly, bispecific antibodies targeting CD3 and tumor-associated antigens (e.g., EGFRvIII) are under development, with early data showing 40% disease control in glioblastoma. These combinations exploit complementary mechanisms to enhance antitumor immunity.

Key Data Points

• Over 1,200 immuno-oncology agents in clinical development as of 2025, with 60% targeting novel pathways beyond PD-1/PD-L1.
• Relatlimab (anti-LAG-3) plus nivolumab improved median progression-free survival to 10.1 months in melanoma, versus 4.6 months with nivolumab alone.
• Magrolimab (anti-CD47) combined with azacitidine achieved a 67% complete response rate in myelodysplastic syndrome.
• Composite biomarker (TMB + T cell clonality) predicted checkpoint inhibitor response with 78% accuracy in a 1,500-patient study.
• T-VEC plus pembrolizumab yielded a 48% objective response rate in melanoma, versus 25% with pembrolizumab alone.

Frequently Asked Questions

What are the most promising emerging immuno-oncology drug targets in 2025?

LAG-3, TIGIT, CD47, NKG2A, and STING are among the most promising novel targets, with multiple Phase II/III trials showing improved outcomes compared to standard therapies.

How do metabolic checkpoints differ from traditional immune checkpoints?

Metabolic checkpoints, such as adenosine A2A receptors and IDO1, regulate immune cell function through nutrient availability and metabolic byproducts, offering a complementary approach to classic immune checkpoints like PD-1.

Can CAR-T therapy be effective for solid tumors?

Yes, emerging targets like B7-H3, mesothelin, and GD2 are showing promise in solid tumor CAR-T trials, particularly when combined with checkpoint inhibitors or armored with cytokine-secreting capabilities.

What biomarkers are used to select patients for novel immuno-oncology targets?

Beyond TMB and PD-L1, interferon-gamma gene signatures, tumor-infiltrating lymphocyte density, and circulating tumor DNA dynamics are increasingly used to stratify patients for targeted therapies.

How are combination strategies advancing immuno-oncology?

Combining novel targets with oncolytic viruses, bispecific antibodies, or checkpoint inhibitors enhances antitumor immunity through synergistic mechanisms, as demonstrated by T-VEC plus pembrolizumab achieving a 48% objective response rate in melanoma.